@article{article_1116584, title={Evaluation of Patients Treated With Omalizumab (Anti-Ige) During The Pandemic Period}, journal={Türkiye Çocuk Hastalıkları Dergisi}, volume={17}, pages={118–125}, year={2023}, DOI={10.12956/tchd.1116584}, author={Karalı, Zuhal and Çekiç, Şükrü and Özdemir, Öner and Canıtez, Yakup and Sapan, Nihat}, keywords={Astım, COVİD-19, Ürtiker, omalizumab}, abstract={<b>Objective: </b> There are few studies investigating the impact of the COVID-19 pandemic on patients using omalizumab. In this study, it was aimed to investigate the effects of the COVID-19 pandemic on our patients who have been treating with omalizumab. <br /> <br /> <b>Material and Methods: </b> From two centers, a total of 20 patients participated in the study. A questionnaire, consisting of 45 questions prepared by our department, and a visual analogue scale (0: minimum, 10: maximum) were applied face-to-face to the patients. <br /> <br /> <b>Results: </b> It was observed that six patients (30%) did not continue their omalizumab treatment during the pandemic period. While 90% (n=18) of the patients were wearing masks, 85% (n=17) stated that they paid attention to social distance. In our study, the frequency of COVID-19 infection in patients using omalizumab was 10% (n=2). With the pandemic, while our patients’ working-study habits were affected negatively (n=10, 50%), their appetite increased (n=8, 40%), and it was noted that there have been changes in their sleep patterns (n=8, 40%). <br /> <br /> <b>Conclusion: </b>The COVID-19 pandemic has significantly affected our patients’ treatments and follow-ups. Our results support the argument that the use of omalizumab does not increase the risk of SARS-CoV-2 infection.}, number={2}, publisher={T.C. Sağlık Bakanlığı Ankara Şehir Hastanesi}